Elegen Reduces Pricing for ENFINIA™ DNA to Expand Access to Next-Generation Cell-Free DNA Manufacturing
Elegen, a pioneer in next-generation cell-free DNA manufacturing, has announced a 25% price reduction for its ENFINIA™ DNA products. This move aims to make the industry-leading, long, complex, NGS-verified DNA more accessible to researchers and biotech innovators. The updated pricing applies to both linear and plasmid ENFINIA DNA products, covering both standard and complex sequence designs.
Elegen, a leading company in next-generation cell-free DNA manufacturing, has announced a significant 25% reduction in pricing for its ENFINIA™ DNA products. This price drop marks a milestone in making industry-leading long, complex, NGS-verified DNA more accessible to researchers and biotech innovators. The new pricing applies to both linear and plasmid ENFINIA DNA products for standard and complex sequence designs. With this update, Elegen continues its commitment to driving innovation in synthetic biology, gene therapy, and mRNA vaccine development by making cutting-edge tools more affordable and accessible.
This pricing change comes as a result of Elegen’s advancements in cell-free cloning technology and the efficiency improvements made possible by their newly established facility. The use of automation and machine learning has significantly increased synthesis success rates, enabling the company to provide high-quality DNA at faster rates. With these advancements, Elegen can now deliver long and complex DNA constructs as quickly as 6 to 8 days, with prices as low as $0.15 per base pair. Additionally, customers who place bulk orders can benefit from even further discounts, making this an attractive option for those in need of large quantities of high-quality DNA.
ENFINIA™ DNA is unique because it is manufactured cell-free, overcoming the limitations inherent in traditional cell-based cloning methods. As a result, ENFINIA DNA offers remarkable lengths and complexity, providing up to 7 kb for linear DNA and up to 18 kb for plasmid DNA. Each construct is rigorously NGS-verified, ensuring high precision, and is ready for immediate use in customer workflows. This capability provides a valuable resource for researchers working on complex synthetic biology projects and other fields requiring high-quality, long DNA sequences.
“We fully expected to lower our pricing as our customer base grew and as we tightened efficiencies in our technology platform,” said Mark Lasinski, Senior Vice President of Sales and Marketing at Elegen. “This enabled us to innovate faster, reduce our cost of goods, and pass those savings along to our customers.
With our continued investment in automation and process optimization, we’re delivering on our mission to help researchers screen and optimize long, complex constructs more quickly. This accelerates candidate selection and, ultimately, helps speed up discovery and development timelines.”
Earlier in the year, Elegen launched its ENFINIA™ Plasmid DNA, a more cost-effective and faster solution for clonal synthesis of long, complex genes. ENFINIA Plasmid DNA offers researchers access to high-complexity clonal genes up to 15 kb, which are NGS-verified and shipped globally from Elegen’s U.S.-based facilities within 10 business days. This additional offering further solidifies Elegen’s commitment to empowering researchers with high-quality, reliable DNA for their projects.
The new pricing update is expected to fuel continued growth and innovation in the synthetic biology sector, particularly in gene and cell therapy, as well as mRNA vaccine development. Elegen’s products enable researchers to accelerate the pace of their discoveries and bring novel therapeutics to market more quickly. The ability to efficiently manufacture long and complex DNA in a cost-effective manner is critical for advancing research in areas such as drug development, genetic engineering, and vaccine production.
Elegen’s proprietary microfluidics-based approach allows for the construction of longer, higher-quality DNA sequences in a significantly shorter timeline compared to traditional methods. This approach is set to revolutionize industries such as agriculture, chemicals, healthcare, and pharmaceuticals by enabling the rapid production of custom DNA at scale. With their innovative technologies and commitment to accelerating progress, Elegen has established itself as a leader in the life sciences field.
About Elegen
Founded in 2017 and based in the San Francisco Bay Area, Elegen is focused on creating high-quality synthetic DNA with a faster turnaround. The company has made significant strides in molecular biology, chemistry, and microfluidics to deliver innovative, scalable DNA manufacturing solutions. Elegen’s cutting-edge technology is already being used across industries including agriculture, healthcare, and pharmaceuticals, with a focus on synthetic biology, gene therapy, and mRNA vaccine development. By making high-quality DNA products more accessible and affordable, Elegen continues to play a key role in advancing the future of life sciences.
